Shares of Genzyme Corp. dropped $3.12, or 5.9 percent, to $50.05 this afternoon after the announcement that federal health regulators found tiny particles of trash in drugs made by the biotechnology firm.
The Food and Drug Administration said that bits of steel, rubber and fiber found in vials of drugs used to treat rare enzyme disorders could cause serious adverse health effects for patients. This is the second case of contamination for Genzyme—last June, the company was forced to shut down a key production facility due to viral contamination.
The FDA will not remove the products from the market due to the fact that there are few alternative treatments, and advise doctors to closely inspect vials for particles before injecting them into patients. The agency also said that the contamination only affected about one percent of Genzyme’s products, and no adverse events have been reported yet.
About EQUITIES:
Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.
Sign up for a free one-year subscription to EQUITIES Magazine
